Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,616.50
Bid: 1,618.00
Ask: 1,618.50
Change: 4.50 (0.28%)
Spread: 0.50 (0.031%)
Open: 1,607.50
High: 1,620.00
Low: 1,594.00
Prev. Close: 1,612.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-European stocks end flat between Asia worries, British re-opening cheer

Mon, 17th May 2021 09:43

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* Asia restrictions, China data weigh

* Kinnevik jumps to top of STOXX 600

* Spain's Telefonica gains as it seeks buyers for delivery
arm

* Sanofi, GSK gain as COVID-19 vaccine shows immune response
(Updates with market close)

By Shashank Nayar and Sruthi Shankar

May 17 (Reuters) - European stocks ended flat on Monday as
underwhelming Chinese data and caution over the spread of a
COVID-19 variant outweighed optimism on the reopening of the
British economy, while Sweden's Kinnevik surged and was the top
performer.

The pan-European STOXX 600 index ended flat with
travel and leisure stocks being the top losers, down
2.3%, while telecommunication stocks jumped the most,
led by gains in Spanish telecom firm Telefonica

Dampening sentiment was data showing that China's factories
slowed their output growth in April and retail sales
significantly missed expectations as officials warned of new
problems affecting the economic recovery.

Meanwhile, fresh restrictions across Asia following a new
wave of COVID-19 cases and concerns over the spread of a
fast-spreading coronavirus variant first identified in India
overshadowed optimism on UK's economic reopening.

"Airlines are on the back foot once again today, with
optimism over the reopening of international travel proving
short-lived given concerns over the growth of the Indian COVID
variant," said Joshua Mahony, senior market analyst at IG.

"Unfortunately, the risks posed by this latest strain also
raise questions around those same businesses that have just
found reprieve from lockdown restrictions, with pub and
restaurant chains all on the back foot despite the resumption of
indoor dining," added Mahony.

Britain's domestically focused mid-cap index dropped
0.6%, with restaurant and pub operator SSP Group and
airlines Easyjet and Wizz Air Holdings being
the top drags.

Irish airline Ryanair fell 2.8% after reporting a
record annual after-tax loss, as it said there were signs the
recovery had begun.

European stocks have performed well so far and surged to
all-time highs this month, with the STOXX 600 up nearly 11% so
far this year as economic recovery prospects and strong earnings
drew buyers of equities.

The European Union has agreed to a partial truce with the
United States in a dispute over metal tariffs imposed by former
President Donald Trump and to start discussions on global
overcapacity and China's "trade-distorting" policies.

Mining stocks gained 0.9%.

In corporate news, Sweden's Kinnevik jumped 8.5%
to the top of the STOXX 600 index after the company transferred
its stake in online fashion retailer Zalando to
shareholders.

Spanish telecoms group Telefonica gained 3.5% as it
is seeking buyers for its logistics and express-delivery unit
Zeleris, a source familiar with the offer said on Monday, amid a
months-long boom in the business as COVID-19 pushes people to
shop online.

Drugmakers Sanofi and GlaxoSmithKline
jumped 1% and 0.7% respectively after their experimental
COVID-19 vaccine showed a robust immune response in early-stage
clinical trial results, enabling them to move to a late-stage
study.
(Reporting by Sruthi Shankar and Shashank Nayar in Bengaluru;
Editing by Subhranshu Sahu and Dan Grebler)

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.